More intensive chemo ups survival in ewing sarcoma

October 29, 2012

(HealthDay)—More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of Clinical Oncology.

Richard B. Womer, M.D., from the Children's Hospital of Philadelphia, and colleagues conducted a prospective trial in which 568 patients younger than 50 years old with newly diagnosed localized extradural Ewing sarcoma were randomized to receive standard or intensified treatment with chemotherapy cycles beginning every 21 and 14 days, respectively (284 patients in each group). Patients received vincristine, , and alternating with ifosfamide and etoposide for 14 cycles, with filgrastim between cycles. At week 13, following four cycles in the standard arm and six cycles in the intensified arm, primary tumor treatment (surgery, radiation, or both) began.

The researchers found that, at a median of five years, event-free survival was 65 percent in the standard arm and 73 percent in the intensified arm (P = 0.048). Toxicity was similar between the groups.

"For localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than administered every three weeks, with no increase in toxicity," the authors write.

Explore further: More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.